18/12/2017 Acetylsalicylic acid 99.

0% | Sigma-Aldrich

Indonesia Home A5376 - Acetylsalicylic acid

A5376 SIGMA

Acetylsalicylic acid
99.0%
Synonym: 2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

SDS SIMILAR PRODUCTS

CAS Number 50-78-2 Linear Formula 2-(CH3CO2)C6H4CO2H Molecular Weight 180.16

Beilstein Registry Number 779271 EC Number 200-064-1 MDL number MFCD00002430

PubChem Substance ID 24278218

POPULAR DOCUMENTS: SPECIFICATION SHEET (PDF) | FTNMR (PDF)

Properties
Related Categories A to C, Application Index, Arachidonic Acid Cascade,
Biochemicals and Reagents, Cancer Research,
More...

InChI Key BSYNRYMUTXBXSQ-UHFFFAOYSA-N

assay 99.0%

form powder

color white

pKa (25 C) 3.5

mp 134-136 C(lit.)

solubility H2O: 10 mg/mL at 37 C(lit.)

Show More (16)

Description

Frequently Asked Questions

Frequently Asked Questions are available for this Product.

Biochem/physiol Actions
Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The
antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against
colorectal and other solid tumors.

Packaging
1 kg in poly bottle

100, 250, 500 g in poly bottle

Price and Availability

Price
SKU-Pack Size Availability Quantity
(SGD)

A5376-100G Available to ship on 18.12.2017 - FROM 41.37 0

A5376-250G Available to ship on 18.12.2017 - FROM 73.50 0

A5376-500G Estimated to ship on 08.01.2018 - FROM 119.18 0

A5376-1KG Estimated to ship on 03.01.2018 - FROM 222.60 0

BULK ORDERS? ADD TO CART

https://www.sigmaaldrich.com/catalog/product/sigma/a5376?lang=en&region=ID 1/5
18/12/2017 Acetylsalicylic acid 99.0% | Sigma-Aldrich

Personalized Product Recommendations

S5922 A7085
Salicylic acid Acetaminophen
BioXtra, 99.0% BioXtra, 99.0%

Customers Also Viewed

S5922 A7085 A6810 I4883 A3035

Salicylic acid Acetaminophen Acetylsalicylic acid Ibuprofen Acetaminophen
BioXtra, 99.0% BioXtra, 99.0% BioReagent, plant cell 98% (GC) analytical standard
culture tested, 99.0%

A2093 PHR1003 247588 W398500 C0750

Aspirin Aspirin (Acetyl Salicylic Acid) Salicylic acid Salicylic acid Caffeine
meets USP testing pharmaceutical secondary ACS reagent, 99.0% 99%, FG powder, ReagentPlus
specifications standard; traceable to USP,
PhEur and BP

https://www.sigmaaldrich.com/catalog/product/sigma/a5376?lang=en&region=ID 2/5
18/12/2017 Acetylsalicylic acid 99.0% | Sigma-Aldrich

Recently Viewed

A6404 91204 539996 242845

Acetic anhydride Acetic anhydride Acetic anhydride Acetic anhydride
reagent grade, 98% for GC derivatization, 99.5% ACS reagent, 98.0%
99.0%

320102
Acetic anhydride
ReagentPlus, 99%

Safety Information Documents

Symbol Certificate of Analysis Certificate of Origin

GHS07
Enter Lot No. Enter Lot No.

Signal word Warning Bulk Quote-Order Product SDS

Hazard statements H302-H315-H319-H335 Specification Sheet Ask A Scientist

Celltransmissions 20(1) (80 KB ) Celltransmissions 20(2) (366 KB )

Precautionary statements P261-P305 + P351 + P338
FT-IR Raman FT-NMR
Personal Protective Equipment dust mask type N95 (US), Eyeshields,
Faceshields, Gloves Structure Search

RIDADR NONH for all modes of transport

WGK Germany 1

RTECS VO0700000

Flash Point(F) 482 F

Flash Point(C) 250 C

Frequently Asked Questions

Which document(s) contains shelf-life or expiration date information for a given product?
If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis. These documents are located on the product detail page
under Useful Links & Tools. Click on the following link to search for a Certificate of Analysis. Please click the following link to see the details on our Product Dating Information.

How do I get lot-specific information or a Certificate of Analysis?

A Certificate of Analysis is available by lot number and can be obtained through our Advanced Search Option: http://www.sigmaaldrich.com/catalog/AdvancedSearchPage.do

How do I find price and availability?

There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can
contact any of our Customer Sales and Service offices to receive a quote. USA customers: 1-800-325-3010 or view local office numbers.

What is the Department of Transportation shipping information for this product?

Transportation information can be found in Section 14 of the product's (M)SDS. To access the shipping information for this material, use the link on the product detail page for the product, or
search here.

My question is not addressed here, how can I contact Technical Service for assistance?
Use the option to the right to "Ask a Question" by email of a Technical Service Scientist.

Show more questions

Peer-Reviewed Papers
https://www.sigmaaldrich.com/catalog/product/sigma/a5376?lang=en&region=ID 3/5
18/12/2017 Acetylsalicylic acid 99.0% | Sigma-Aldrich

Did you use this product in your Paper? If so click here.

read abstract

1. Aspirin in patients undergoing noncardiac surgery.

P J Devereaux et. al
The New England journal of medicine, 370(370), undefined (2014-4-1)
There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both among patients who are already on an aspirin regimen and among those who are
not. Using a 2-by-2 factorial trial design, ...Read More

read abstract

2. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Gregg W Stone et. al
Lancet (London, England), 382(382), undefined (2013-7-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed
to determine the relation between platelet...Read More

read abstract

3. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
Reiko Nishihara et. al
JAMA, 309(309), undefined (2013-6-27)
Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2),
suggesting that BRAF-mutant colonic cells might be less ...Read More

read abstract

4. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Yasuo Ikeda et. al
JAMA, 312(312), undefined (2014-11-18)
Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to an aging population. To determine whether daily, low-dose aspirin reduces the incidence of
cardiovascular events in older Japanese patients ...Read More

read abstract

5. Chemical genetics reveals a complex functional ground state of neural stem cells.
Phedias Diamandis et. al
Nature chemical biology, 3(3), undefined (2007-4-10)
The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain holds promise for the treatment of neurological diseases and has yielded new insight into brain cancer.
However, the complete repertoire of signaling ...Read More

read abstract

6. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial.
Connie N Hess et. al
Journal of the American College of Cardiology, 66(66), undefined (2015-8-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS.
This study examined high-risk ACS patients who ...Read More

read abstract

7. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Simon Thom et. al
JAMA, 310(310), undefined (2013-9-5)
Most patients with cardiovascular disease (CVD) do not take recommended medications long-term. The use of fixed-dose combinations (FDCs) improves adherence in several clinical areas. Previous trials of
cardiovascular FDCs have assessed short-term eff...Read More

read abstract

8. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin.
Niels Hulsman et. al
Journal of medicinal chemistry, 50(50), undefined (2007-4-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an
antitumor drug. We report that, contrary to curre...Read More

read abstract

9. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Martine Gilard et. al
Journal of the American College of Cardiology, 65(65), undefined (2014-12-3)
The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES)xa0recipients is 12 months to reduce the risk of late stent thrombosis, particularly in those with acute
coronary syndrome (ACS). This study hypothesize...Read More

read abstract

10. 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor.
Liu M, Saeki K, Matsunobu T, et al.
The Journal of Experimental Medicine, 211(6)(211(6)), undefined (2014)

read abstract

11. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial.
T N Bonten et. al
Thrombosis and haemostasis, 112(112), undefined (2014-9-12)
The risk of acute cardiovascular events is highest during morning hours, and platelet activity peaks during morning hours. The effect of timing of aspirin intake on circadian rhythm and morning peak of platelet
reactivity is not known. It was our obj...Read More

read abstract

12. Dose- and time-dependent antiplatelet effects of aspirin.

Christina Perneby et. al
Thrombosis and haemostasis, 95(95), undefined (2006-4-8)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline)
with three aspirin dosage regimens--37.5 mg/...Read More

read abstract

13. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.
Laurent Arnaud et. al
Autoimmunity reviews, 13(13), undefined (2013-11-6)
We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+). Observational and
interventional studies identified from the Medline, Em...Read More

read abstract

14. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Gustav Ahlin et. al
Journal of medicinal chemistry, 51(51), undefined (2008-9-16)
The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib. In this study,
we explored the chemical space of regis...Read More

read abstract

15. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Laura Mauri et. al
The New England journal of medicine, 371(371), undefined (2014-11-18)
Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. Patients were enrolled after they had
undergone a coronary stent procedure in ...Read More
Show more references (667 remain)

https://www.sigmaaldrich.com/catalog/product/sigma/a5376?lang=en&region=ID 4/5
18/12/2017 Acetylsalicylic acid 99.0% | Sigma-Aldrich

Related Products

2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Reproduction of any materials
from the site is strictly forbidden without permission. Sigma-Aldrich Products are sold exclusively through Sigma-Aldrich, Inc. Site Use
Terms | Privacy

https://www.sigmaaldrich.com/catalog/product/sigma/a5376?lang=en&region=ID 5/5